Late-breaking phase 3 data at aad 2022 show dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

Tarrytown, n.y. and paris , march 26, 2022 /prnewswire/ -- dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many dupixent patients experienced clinically meaningful reductions in itch and skin lesions there are currently no approved systemic treatments for prurigo nodularis; regulatory filings for dupixent in prurigo nodularis are planned in the first half of 2022 regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi announced that detailed positive results from the phase 3 prime2 trial evaluating the efficacy and safety of dupixent® (dupilumab) were presented today in a late-breaking session at the american academy of dermatology (aad) 2022 annual meeting.
REGN Ratings Summary
REGN Quant Ranking